Scope and US Patent 8,236,861 Landscape for Ospemifene Bioavailability-Timing Methods With Food-Induced Bile Acids
US Drug Patent 8,236,861 claims a narrow but enforcement-ready method: enhancing oral ospemifene (or salts) bioavailability by timing dosing relative to food intake and specifying food having nutritional value that causes bile-acid secretion. The claim set ties the timing window (not earlier than 1 hour before meal start and not later than 2 hours after) to therapeutic end uses (osteoporosis and urogenital/skin/epithelial or mucosal atrophy) and to dose ranges aligned with marketed strengths (30 to 90 mg/day; 60 mg). The patent landscape implication is that generic and branded competitors can face method-of-use and use-in-context infringement risk if they dose in the claimed window and in claimed indications, even if they replicate the marketed formulation.
What does US Patent 8,236,861 claim: timing oral ospemifene with food-induced bile acids?
Claims at a glance (independent claim structure)
The asserted independent claim is structured as a bioavailability-enhancement method requiring four elements:
- Orally administer ospemifene or a pharmaceutically acceptable salt.
- In connection with intake of a foodstuff with nutritional value that causes bile-acid secretion.
- Dose timing relative to meal start: the administration time is within (−1 hour to +2 hours) relative to when food intake starts.
- Result purpose: “to enhance bioavailability.”
From that base, dependent claims narrow timing, indications, and dose.
Time-window scope (core enforceability hook)
Across claims 1 and 11, the independent timing window is:
- From 1 hour before starting the food intake
- To 2 hours after starting the food intake
Dependent refinements include:
- Claim 2: within 1 hour after food intake started (i.e., 0 to +1 hour).
- Claim 3: no later than 0.5 hour after food start (i.e., up to +0.5 hour).
This creates a segmented infringement map:
- If dosing occurs in (−1 to +2), the claim is triggered in principle.
- If dosing is in (0 to +1) or (0 to +0.5), additional dependent-claim coverage becomes more likely.
Food definition and bile-acid secretion requirement
The method requires food that “has nutritional value and causes secretion of bile acids.” This ties infringement to:
- a factual/technical relationship between the administered meal and bile-acid secretion, and
- whether the clinician/patient followed the method “in connection with” such food.
That element is often where validity or noninfringement arguments concentrate, because it can be contested mechanistically and factually.
Therapeutic-use claim add-ons
Dependent claims add clinical context:
- Osteoporosis: claim 4 (and corresponding claim 15 path)
- Skin atrophy and epithelial or mucosal atrophy: claim 7 (and corresponding claim 12 path)
- Specific symptom subcategory: claim 8 for urinary or vaginal symptoms
- Urogenital atrophy framing: claim 18 (and claim 19/20 for dose)
These dependent claims make the patent practically relevant to prescribing instructions and labeling-congruent regimens. If the marketed dosing is close to the window, enforcement risk concentrates.
Dose-range scope
When the claims land in treatment framing, they also specify dose:
- 30 to 90 mg/day: claims 5, 9, 13, 16, 19
- 60 mg: claims 6, 10, 14, 17, 20
The strongest enforcement alignment is if ospemifene is prescribed at 60 mg/day and dosing is timed within the claimed window with meal ingestion meeting the bile-acid secretion criterion.
How broad are US 8,236,861 claims on ospemifene: what’s included and excluded?
Included
- Any oral ospemifene dosing that occurs within the timing window relative to food intake start.
- Use with either ospemifene base or pharmaceutically acceptable salts (claim 1 and claim 18 line).
- Indications included via explicit dependent claims:
- osteoporosis
- skin atrophy
- epithelial/mucosal atrophy
- urinary or vaginal symptom subsets
- urogenital atrophy
Excluded (practical carve-outs)
- Administration outside the window:
- earlier than 1 hour before meal start
- later than 2 hours after meal start
- Food that is not shown to “cause secretion of bile acids.”
- Indications not captured by dependent claims unless asserted under the independent “enhancing bioavailability” method alone.
Note the patent’s independent claim is not tied to a specific indication. That can widen enforcement, because a method to enhance bioavailability can be argued regardless of the clinical label, if the other elements are met.
Which parts of the claim set are most likely to drive infringement?
1) Timing window relative to meal start (most objective trigger)
Timing is usually the easiest feature to map to conduct:
- meal start timestamp
- dosing timestamp
- whether dosing fell within −1 to +2 hours, or within more narrow dependents.
If you’re assessing liability risk, the first gating question is whether the dosing instruction in practice aligns with:
- 0 to +1 hour, or
- up to +0.5 hour, or
- within −1 to +2.
2) Dose strength and regimen (60 mg is a practical alignment point)
Because several dependent claims lock to 60 mg, the patent is easier to apply against real-world prescribing that matches common dosing.
3) Food-induced bile-acid secretion (highest contestability)
The bile-acid secretion clause is where factual or technical disputes can arise. Still, for litigation posture, the clause can be supported using:
- standard physiology literature
- evidence that typical “nutritional” meals stimulate bile secretion
- expert testimony tying meal ingestion to increased bile acids.
What patent landscape surrounds US 8,236,861 for ospemifene bioavailability enhancement?
Positioning within the ospemifene IP stack
US 8,236,861 is best characterized as a pharmacokinetic optimization patent:
- It does not claim the molecule.
- It does not claim a formulation composition (based on provided claim text).
- It claims administration method conditions that improve exposure via a physiologic mechanism: food-triggered bile-acid secretion.
In an ecosystem view, this often sits alongside:
- earlier composition/formulation patents (if any)
- later method-of-use patents for specific indications
- regulatory exclusivity periods for brand ospemifene (if expired, this method can be the residual lever)
Because the claim set is operational and timing-based, it can remain valuable even when composition and use patents begin to age out.
Landscape dynamics relevant for generics
A generic entrant can potentially avoid:
- literal infringement if dosing is scheduled outside the window
- dependent-claim infringement if it avoids the 30–90 mg range or the 60 mg regimen (less practical)
But the independent claim creates risk if the generic prescribing mirrors timing in routine practice.
When does US 8,236,861 expire and how does that affect generic launch risk?
No filing, priority, maintenance, terminal disclaimer, or expiration data is provided in the prompt. Without those inputs, an expiration timeline cannot be produced accurately.
Because your request is for a detailed, business-grade analysis, the only accurate conclusion is: an exclusivity and expiration timeline cannot be stated from the claim text alone.
What validity issues could be asserted against US 8,236,861 based on the claim content?
Potential obviousness framing around meal timing and bioavailability
The method is essentially: dose timing within a meal-relative window to exploit bile secretion. Validity arguments typically test whether:
- the concept of administering drugs with meals to affect bile flow or solubilization was known,
- the specific timing window (−1 to +2; plus dependents) was an obvious optimization,
- the bile-acid secretion requirement is a meaningful distinguishing parameter versus routine meal effects.
Potential indefiniteness or overbreadth around “foodstuff … causing bile acids”
The claim does not specify:
- meal composition,
- bile-acid thresholds,
- measurable endpoints,
- patient variability.
If the patent is enforced broadly, defendants may argue the claim reads on many foods without a clear boundary.
How strong is US 8,236,861 for licensing: what is the “work product” being protected?
The value proposition for licensing is that the patent protects a behavioral prescribing tactic:
- “when” to administer ospemifene in relation to food intake and bile stimulation,
- combined with real-world dosing levels (30–90 mg/day; 60 mg).
This makes the IP potentially attractive to:
- branded parties wanting to defend market exclusivity tactics after core formulation/use exclusivities diminish,
- generic sponsors that seek negotiated labeling or administration instruction carve-outs to reduce method-liability exposure.
What would a Paragraph IV or generic entry strategy look like versus US 8,236,861?
Likely generic design-around avenues
Based on claim language alone, the most straightforward design-around is operational:
- changing dosing instructions to move dosing outside −1 to +2 hours relative to meal start.
A second axis is clinical differentiation:
- avoiding the specific dependent claim regimen by choosing different dosage strengths or labeling.
But because the independent claim is indication-agnostic, changing indication alone is not enough if the dosing timing and bile-acid triggering elements remain.
Litigation posture expectations
Because infringement is tied to timing and physiologic mechanism, litigation tends to turn on:
- patient dosing documentation,
- prescribing practices,
- expert testimony on whether the relevant meal category causes bile-acid secretion,
- and whether generic or branded labeling aligns with the claimed window.
How does US 8,236,861 compare with typical ospemifene patent types (composition vs use vs method-of-administration)?
Comparison map
- Composition/formulation patents: protect what the pill is.
- Method-of-use patents: protect why the pill is taken (indication).
- Method-of-administration patents like US 8,236,861: protect how it is taken (timing relative to meal physiology).
US 8,236,861 sits in the third category, which can remain relevant even after formulation and earlier use claims narrow, because it can be asserted based on real-world administration conduct.
Key claim-by-claim scope summary (operational checklist)
| Claim |
Core requirement |
Added narrowing |
| 1 |
Enhance oral ospemifene/salt bioavailability via dosing during −1 to +2 hours around meal start; food has nutritional value and causes bile-acid secretion |
Indication not required |
| 2 |
Same as claim 1 |
Dose in 0 to +1 hour |
| 3 |
Same as claim 1 |
Dose no later than +0.5 hour |
| 4 |
Same as claim 1 |
Use for osteoporosis |
| 5 |
Same as claim 4 |
Oral dosage 30–90 mg/day |
| 6 |
Same as claim 5 |
Dose 60 mg |
| 7 |
Same as claim 1 |
Use for skin atrophy or epithelial/mucosal atrophy |
| 8 |
Same as claim 7 |
Atrophy symptoms are urinary or vaginal |
| 9 |
Same as claim 7 |
Oral dosage 30–90 mg/day |
| 10 |
Same as claim 9 |
Dose 60 mg |
| 11 |
Enhance bioavailability of ospemifene (not explicitly salts) using −1 to +2 window |
Molecular scope narrower vs claim 1 |
| 12 |
Same as claim 11 |
Atrophy indication |
| 13 |
Same as claim 12 |
30–90 mg/day |
| 14 |
Same as claim 13 |
60 mg |
| 15 |
Same as claim 11 |
Osteoporosis indication |
| 16 |
Same as claim 15 |
30–90 mg/day |
| 17 |
Same as claim 16 |
60 mg |
| 18 |
Inhibit urogenital atrophy via dosing during −1 to +2 window with bile-acid secretion meal |
Includes urogenital atrophy treatment framing |
| 19 |
Same as claim 18 |
30–90 mg/day; oral |
| 20 |
Same as claim 19 |
Dose 60 mg |
Key Takeaways
- US 8,236,861 is a bioavailability-timing patent for oral ospemifene: it requires dosing in a meal-relative window of −1 hour to +2 hours with nutritional food that causes bile-acid secretion.
- The enforceability focus is likely the timing window and, in dependent claims, 60 mg/day regimens.
- The most litigated feature is likely the bile-acid secretion requirement tied to the meal, due to definitional and evidentiary variability.
- Generic and licensing strategies will need to address prescribing and administration timing, not only formulation equivalence.
FAQs
1) Can US 8,236,861 be infringed without a specific osteoporosis or atrophy indication?
Yes, because the independent claim is framed as enhancing ospemifene bioavailability and does not require a particular clinical indication.
2) What dosing times are covered by the patent’s broadest claim?
Dosing must occur between 1 hour before starting food intake and 2 hours after food intake starts.
3) Are 0 to +1 hour and +0.5 hour dosing positions covered more tightly?
Yes. Dependent claims narrow the timing to within 1 hour after meal start (claim 2) and no later than 0.5 hour after meal start (claim 3).
4) Does the patent require salts or only ospemifene base?
Claim 1 explicitly covers ospemifene or pharmaceutically acceptable salts. Claim 11 focuses on ospemifene.
5) What dose levels are repeatedly called out in dependent claims?
Dependent claims consistently track 30 to 90 mg/day and repeatedly specify 60 mg.
References (APA)
- United States Patent and Trademark Office. (n.d.). US Patent 8,236,861.
